Reuters logo
BRIEF-Camurus says FDA grants priority review of NDA for weekly and monthly CAM2038 Buprenorphine depots
September 18, 2017 / 8:33 AM / a month ago

BRIEF-Camurus says FDA grants priority review of NDA for weekly and monthly CAM2038 Buprenorphine depots

Sept 18 (Reuters) - Camurus Ab

* Camurus announces that FDA grants priority review of NDA for weekly and monthly CAM2038 buprenorphine depots for treatment of opioid use disorder

* NDA for CAM2038 submitted on July 19 by Camurus’ U.S. Partner Braeburn, comprises data from seven clinical trials, including two phase 3 trials Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below